FTC sees 'turning point' in battle against pay-for-delay

The U.S. government's decade-long fight to limit drugmakers' ability to keep generic medicines off the market may reach "a turning point" soon, Federal Trade Commission Chairman Jonathan Leibowitz told Bloomberg. Report